CN104306354A - Finasteride oral instant membrane - Google Patents
Finasteride oral instant membrane Download PDFInfo
- Publication number
- CN104306354A CN104306354A CN201410489303.4A CN201410489303A CN104306354A CN 104306354 A CN104306354 A CN 104306354A CN 201410489303 A CN201410489303 A CN 201410489303A CN 104306354 A CN104306354 A CN 104306354A
- Authority
- CN
- China
- Prior art keywords
- finasteride
- oral instant
- agent
- add
- instant membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a finasteride oral instant membrane agent and a preparation method thereof, wherein the finasteride oral instant membrane agent comprises an effective dose of the active component finasteride, a polymer film-forming material, a plasticizer, an assistant suspending agent, a flavoring agent, a coloring agent and the like. The finasteride oral instant membrane agent is mainly used for treatment of male alopecia or prostatic hyperplasia.
Description
Technical field
The invention belongs to medical art, relate to a kind of oral formulations being used for the treatment of male pattern baldness or prostatic hyperplasia, be specifically related to a kind of instant membrane comprising finasteride and preparation method thereof.
Background technology
Research display, people more than 50% in more than the 50 years old male in the whole world suffers from male pattern alopecia, and male pattern alopecia is 15.7% ~ 19.75% in the prevalence of China, although alopecia can not be unhealthful, but psychological burden can be brought to patient, the life and work of patient is made troubles.
Pathogeny for alopecia is not yet determined, but in its crown of male having research to show genetic predisposition and the scalp pushing up anterior alopecia position, a kind of special hormone---the concentration level of dihydrotestosterone (referred to as DHT) is very high, and this DHT can impel hair follicle atrophy, shorten the growth cycle of hair, cause hair soft, sparse, come off.Testosterone is transformed by the protease of 5α-reductase that cries a kind of in body by DHT, and the male that congenital 5α-reductase lacks would not suffer from alopecia.
Finasteride is a kind of specific inhibitor of 5α-reductase, belong to resistance amcinonide, it can stop testosterone to be converted to dihydrotestosterone, reduce the synthesis of dihydrotestosterone, reduce the content of dihydrotestosterone in scalp hair follicles and serum, make downtrod hair follicle nipple hair growth promoting functional rehabilitation, promote natural on-off cycles of hair growth and prevent from continuing alopecia, finasteride is the only oral drug being used for the treatment of male pattern alopecia that current FDA Food and Drug Administration FDA ratifies, and recommended dose is a 1mg.
Prostatic hyperplasia (BPH) is one of male senile patient common disease, along with the trend of aged tendency of population, and the unsound living habit such as excessive drinking, the onset of illness of prostatic hyperplasia is cumulative many.The medicine for the treatment of prostatic hyperplasia, think at present have certain effect for 5α-reductase inhibitor, alpha-blocking agent, androgen antagonist and a few class such as derivant, plant amedica.Wherein, 5α-reductase is the important enzyme that testosterone changes to dihydrotestosterone.Research shows, dihydrotestosterone has certain effect in prostatic hyperplasia, adopts 5α-reductase inhibitor can give certain suppression to hypertrophy.Finasteride alternative suppresses 5α-reductase, testosterone is stoped to change into the process of 5α-dihydrotestosterone (DHT), Serum Testosterone Levels in prostatic cell is declined, prostate specific antigen in serum reduces, the prostate volume increased reduces, urinary flow increases, thus alleviates patients symptomatic, reaches the object for the treatment of prostatic hyperplasia.The action character of this medicine optionally can block androgen to prostatic stimulation, but seldom affects the sexual function of man.Finasteride is China's treatment prostatic hyperplasia and prostatitic a kind of basic pharmaceutical, and recommended dose is a 5mg.
The current administration of finasteride is mainly with oral tablet, capsule, dispersible tablet form, and need in preparation to add several adjuvant, preparation process is comparatively complicated, and through compression forming, therefore need easily occur the problem of dissolution and bioavailability.Drug effect is by the impact of process in leaching, and onset is slower.Oral instant membrane is as a kind of novel form, preparation process is relatively simple, have the advantages that to meet the rapid disintegrate of water energy and melt, be exposed in oral cavity in saliva and can dissolve rapidly in 60s, medicine is disperseed completely, be conducive to medicine to absorb at gastrointestinal, improve the bioavailability of medicine, onset is rapid.And the preparation technology of oral instant membrane is comparatively simple, and outward appearance is lightly easy to carry, and its instant feature without the need to swallowing with water is also particularly suitable for old man and has the patient of dysphagia to take.
The present invention is devoted to finasteride to be prepared into stable oral instant film preparation.Adopt the adjuvant such as filmogen, plasticizer, be prepared into good mouthfeel, dosage is accurate, be applicable to the oral instant membrane of child and old man.
Summary of the invention
The object of the present invention is to provide a kind of oral instant membrane containing finasteride, this dosage form fater disintegration in the oral cavity, and be easy to carry, improve patient compliance, simultaneously because dosage changing form can dissolve rapidly, improve the bioavailability of this medicine.
Finasteride oral instant membrane of the present invention, comprises component as follows:
Finasteride
Macromolecule filming material
Plasticizer
Suspending agent
Correctives and coloring agent
Other adjuvants.
Described macromolecule filming material comprises hypromellose, hydroxypropyl cellulose, hyaluronate sodium, polyvidone, sodium carboxymethyl cellulose, poly(ethylene oxide), polyvinyl alcohol, maltodextrin, the one in sodium alginate or its mixture, concentration range is 50% ~ 70%(w/w).
Described plasticizer comprises glycerol; propylene glycol; propenyl; low molecular poly; phthalic acid salt derivative such as dimethyl, diethyl adjacent benzene first adipate, citrate derivatives is tributyl, triethyl group, acetyl citrate salt such as; one in glyceryl triacetate and Oleum Ricini or its mixture, concentration range is 10 ~ 40%(w/w).
Described suspending agent comprises xanthan gum, carob gum and some fibre element analog derivative (ethyl cellulose, hydroxyethyl-cellulose, methylcellulose, hydroxypropyl emthylcellulose etc.), one in colloidal silica or its mixture, concentration range is 0 ~ 5%(w/w).
Described correctives comprises one in aspartame, cyclamate, acesulfame potassium, steviosin, sucralose, Mint Essence or its mixture, and concentration range is 0.01% to 0.5%(w/w).It is some colors such as titanium dioxide that described coloring agent comprises, FD & C dyestuff etc., and concentration range is 0.01% to 0.5%(w/w).
Other described adjuvants include but not limited to that filler comprises mannitol, starch, sucrose, lactose, the one in sorbitol or its mixture; Disintegrating agent comprises microcrystalline Cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, the one in pregelatinized Starch or its mixture, and concentration range is 0 ~ 5%(w/w).
Described finasteride oral instant membrane, can disperse by rapid solution in water, and energy disintegrate completely in 60s in the water of 37 DEG C, principal agent finasteride can be uniformly dispersed.
Described finasteride oral instant membrane, has certain toughness and folding strength.
Present invention also offers a kind of method preparing finasteride oral instant membrane: solvent casting method.The method comprises:
(1) above-mentioned macromolecule filming material is dissolved in water, add plasticizer and other adjuvants, obtain uniform glue.
(2) principal agent finasteride is added above-mentioned glue, then add suspending agent, correctives and pigment, stir, obtain medicine glue, place deaeration under vacuum.
(3) said medicine glue is coated with scrapes to on backing, high temperature drying, the demoulding, after cutting into certain size, both pack.
Finasteride oral instant membrane provided by the present invention has quickly disintegrated feature, and membrane can in the complete disintegrate of 60s in 37 DEG C of water, and principal agent disperses completely.When membrane provided by the invention is exposed in saliva, can fater disintegration in the oral cavity, improve the compliance of the patient of dysphagia.Principal agent finasteride principal agent is by gastrointestinal absorption, and identical with former tablet absorption features, bioavailability is similar.
Finasteride oral instant membrane provided by the present invention has certain toughness and folding strength, when do not affect stripping, disintegrate and mouthfeel, there is toughness and the folding strength of suitable intensity, be conducive to patient and carry, take.
Specific embodiment
Embodiment 1: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 10g
Propylene glycol 5g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 10g hypromellose dissolves completely, add 2.5g finasteride, stir and make it be uniformly dispersed, add 0.02g sunset yellow and stir.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
Embodiment 2: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 12g
Propylene glycol 5g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 12g hypromellose dissolves completely, add 2.5g finasteride, stir and make it be uniformly dispersed, add 0.02g sunset yellow and stir.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
Embodiment 3: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 15g
Propylene glycol 5g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 15g hypromellose dissolves completely, add 2.5g finasteride, stir and make it be uniformly dispersed, add 0.02g sunset yellow and stir.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
According to embodiment 1 ~ 3, compare appearance character, the mechanical performances such as the film property of membrane during filmogen hypromellose different amounts, be specified to the consumption of membrane material.
The selection result of table 1 filmogen
| Embodiment | Film property | Release property | Color uniformity | Toughness | Folding strength | Thickness |
| 1 | Well | The easy demoulding | Surface is in speckle shape | Better | Generally | Thinner |
| 2 | Well | The easy demoulding | Surface is in speckle shape | Better | Better | Moderate |
| 3 | Well | The easy demoulding | Surface is in speckle shape | Better | Good | Thicker |
As seen from the above table, the sample of embodiment 1 ~ 3, film property is good, is all easy to the demoulding, and toughness is better, but membrane surface all presents speckle shape, uneven.And can find, along with hypromellose consumption increases, membrane thickness slightly increases, and folding strength improves.The thickness of comprehensive membrane and other appearance property, mechanical performance, the prescription of preferred embodiment 2.
The uneven one-tenth speckle shape in membrane surface may be because principal agent is suspension, skewness in glue, can improve by adding suspending agent.
Embodiment 4: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 12g
Propylene glycol 5g
Colloidal silica 0.8g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 15g hypromellose dissolves completely, add 2.5g finasteride, stirring makes it be uniformly dispersed, and adds 0.8g colloidal silica and stirs, and adds 0.02g sunset yellow and stirs.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
Embodiment 5: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 12g
Propylene glycol 5g
Xanthan gum 0.8g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 15g hypromellose dissolves completely, add 2.5g finasteride, stir and make it be uniformly dispersed, add 0.8g xanthan gum to stir, add 0.02g sunset yellow and stir.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
Embodiment 4,5 is investigated on the basis of embodiment 2, adds different types of suspending agent, investigates the deployment conditions of principal agent in medicine glue, by indexs such as the color uniformity of gained membrane outward appearance, selects suitable suspending agent.
Table 2 suspending agent affects result to membrane
| Embodiment | Film property | Release property | Color uniformity | Toughness | Folding strength | Thickness |
| 4 | Well | The easy demoulding | Homogeneous transparent | Better | Better | Moderate |
| 5 | Well | The not easily demoulding | Speckle shape | Better | Better | Moderate |
According to known in upper table, in embodiment 4, add colloidal silica, membrane filming performance better, be easy to that the demoulding, appearance uniform are transparent, toughness and folding strength better, thickness is moderate.Add xanthan gum in embodiment 5, better but the not easily demoulding, surface are better in speckle shape, toughness and folding strength, thickness is moderate for membrane filming performance.So the prescription of preferred embodiment 4.
Get above-described embodiment 4 sample, be cut into 1.5cm*3cm size membrane 6, measuring its disintegration is 73s, and according to the requirement of oral instant membrane, its disintegration should at 60s, therefore investigates and add disintegrating agent, improves the disintegration of membrane.
Embodiment 6: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 12g
Propylene glycol 5g
Colloidal silica 0.8g
Carboxymethyl starch sodium 0.5g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 15g hypromellose dissolves completely, add after 0.5g carboxymethyl starch sodium dissolves completely, add 2.5g finasteride, stir and make it be uniformly dispersed, add 0.8g colloidal silica to stir, add 0.02g sunset yellow and stir.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
Embodiment 7: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 12g
Propylene glycol 5g
Colloidal silica 0.8g
Low-substituted hydroxypropyl cellulose 0.5g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 15g hypromellose dissolves completely, add after 0.5g low-substituted hydroxypropyl methylcellulose dissolves completely, add 2.5g finasteride, stir and make it be uniformly dispersed, add 0.8g colloidal silica to stir, add 0.02g sunset yellow and stir.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
Embodiment 8: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 12g
Propylene glycol 5g
Colloidal silica 0.8g
Polyvinylpolypyrrolidone 0.5g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 15g hypromellose dissolves completely, add after 0.5g polyvinylpolypyrrolidone dissolves completely, add 2.5g finasteride, stir and make it be uniformly dispersed, add 0.8g colloidal silica to stir, add 0.02g sunset yellow and stir.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
Embodiment 9: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 12g
Propylene glycol 5g
Colloidal silica 0.8g
Pregelatinized Starch 0.5g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 15g hypromellose dissolves completely, add after 0.5g pregelatinized Starch dissolves completely, add 2.5g finasteride, stir and make it be uniformly dispersed, add 0.8g colloidal silica to stir, add 0.02g sunset yellow and stir.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
Get above-described embodiment 6 ~ 9 sample, be cut into 1.5cm*3cm size membrane respectively, respectively get 6, observe its appearance character and measure disintegration, result is as follows:
Table 3 disintegrating agent affects result to membrane character
| Embodiment | Membrane outward appearance | Disintegration (s) |
| 6 | Evenly | 35 |
| 7 | There is granule insoluble matter | 47 |
| 8 | Evenly | 66 |
| 9 | There is granule insoluble matter | 71 |
As seen from the above table, the membrane appearance uniform of embodiment 6 gained is transparent, is limited to 35s during average disintegration.The membrane outward appearance of embodiment 7 gained has granule insoluble matter, is limited to 47s during average disintegration.The membrane appearance uniform of embodiment 8 gained is transparent, is limited to 66s during average disintegration.The membrane outward appearance of embodiment 9 gained has granule insoluble matter, is limited to 71s during average disintegration.To sum up, the prescription of preferred embodiment 6.
Embodiment 10: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 12g
Propylene glycol 5g
Colloidal silica 0.8g
Carboxymethyl starch sodium 0.5g
Sucralose 0.05g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 15g hypromellose dissolves completely, add after 0.5g carboxymethyl starch sodium dissolves completely, add 2.5g finasteride, stir and make it be uniformly dispersed, add 0.8g colloidal silica, 0.05g sucralose stirs, add 0.02g sunset yellow and stir.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
Embodiment 11: recipe quantity is 500, specification 5mg
Finasteride 2.5g
Hyaluronate sodium 0.3g
Hypromellose 12g
Propylene glycol 5g
Colloidal silica 0.8g
Carboxymethyl starch sodium 0.5g
Mint Essence 0.05g
Sunset yellow 0.02g
Pure water 100ml
Technique:
Take 5g propylene glycol, mix homogeneously with 100ml water, add 0.3g hyaluronate sodium stir to be dissolved after, add after 15g hypromellose dissolves completely, add after 0.5g carboxymethyl starch sodium dissolves completely, add 2.5g finasteride, stir and make it be uniformly dispersed, add 0.8g colloidal silica, 0.05g Mint Essence stirs, add 0.02g sunset yellow and stir.By this medicine glue blade coating on backing, in 60 DEG C of oven dry, the demoulding, after cutting into certain size, packs.
According to embodiment 10,11, its gained membrane appearance character and mechanical performance all good.Embodiment 10 gained membrane mouthfeel is partially sweet; Embodiment 11 gained membrane cool taste, is easy to bedding and clothing user and accepts.So, the prescription of preferred embodiment 11.
Claims (8)
1. a finasteride oral instant membrane, is characterized in that it is the medicament prepared by weight percentage by following principal agent and adjuvant:
Finasteride 1 ~ 15%
Macromolecule filming material 50 ~ 70%
Plasticizer 10 ~ 40%
Suspending agent 0 ~ 5%
Correctives and coloring agent 0.01 ~ 0.5%
Other adjuvants 0 ~ 5%.
2. finasteride oral instant membrane according to claim 1, it is characterized by described macromolecule filming material and be selected from hypromellose, hydroxypropyl cellulose, hyaluronate sodium, polyvidone, sodium carboxymethyl cellulose, poly(ethylene oxide), polyvinyl alcohol, maltodextrin, the one in sodium alginate or its mixture.
3. finasteride oral instant membrane according to claim 1; it is characterized by described plasticizer and be selected from glycerol; propylene glycol; propenyl; low molecular poly, phthalic acid salt derivative such as dimethyl, diethyl adjacent benzene first adipate; citrate derivatives is tributyl, triethyl group, acetyl citrate salt such as, the one in glyceryl triacetate and Oleum Ricini or its mixture.
4. finasteride oral instant membrane according to claim 1, it is characterized by described suspending agent and be selected from xanthan gum, carob gum and some fibre element analog derivative (ethyl cellulose, hydroxyethyl-cellulose, methylcellulose, hydroxypropyl emthylcellulose etc.), the one in colloidal silica or its mixture.
5. finasteride oral instant membrane according to claim 1, other adjuvants described include but not limited to that filler is selected from mannitol, starch, sucrose, lactose, the one in sorbitol or its mixture; Disintegrating agent is selected from microcrystalline Cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, the one in pregelatinized Starch or its mixture; Correctives or flavoring agent are selected from one in aspartame, cyclamate, acesulfame potassium, steviosin, sucralose, Mint Essence or its mixture; Pigment is selected from titanium dioxide, FD & C dyestuff.
6. finasteride oral instant membrane according to claim 1, is characterized in that, can disperse by fater disintegration in water, can dissolve completely in 60s in the water of 37 DEG C, principal agent finasteride can be uniformly dispersed.
7. finasteride oral instant membrane according to claim 1, is characterized in that, has certain toughness and folding strength.
8. the method preparing the finasteride oral instant membrane according to claim 1 ~ 7 any one is a solvent casting method, comprises the steps:
(1) macromolecule filming material, plasticizer, other adjuvants are dissolved in water, stir;
(2) principal agent finasteride is dispersed in above-mentioned glue, adds suspending agent, correctives and coloring agent, stir and make it disperse, leave standstill or ultrasonicly make its deaeration;
(3) above-mentioned macromolecule glue is evenly coated with scrapes on backing, high temperature drying, demoulding, after cutting into certain size, both pack.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410489303.4A CN104306354A (en) | 2014-09-24 | 2014-09-24 | Finasteride oral instant membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410489303.4A CN104306354A (en) | 2014-09-24 | 2014-09-24 | Finasteride oral instant membrane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104306354A true CN104306354A (en) | 2015-01-28 |
Family
ID=52361770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410489303.4A Pending CN104306354A (en) | 2014-09-24 | 2014-09-24 | Finasteride oral instant membrane |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306354A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104958279A (en) * | 2015-06-27 | 2015-10-07 | 万特制药(海南)有限公司 | Loratadine oral quickly-soluble film and preparation method thereof |
| CN105663096A (en) * | 2016-01-25 | 2016-06-15 | 南京济群医药科技有限公司 | Vonoprazan oral quick-dissolving film agent and method for preparing same |
| CN107106512A (en) * | 2015-11-25 | 2017-08-29 | 缇碧艾姆株式会社 | Stop blooding and Wound protection film in oral cavity |
| CN118252821A (en) * | 2024-05-28 | 2024-06-28 | 山东则正医药技术有限公司 | Teriflunomide oral solution film bioequivalent to tablet and its prepn and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051344A2 (en) * | 2003-11-25 | 2005-06-09 | Pliva-Lachema A.S. | Oral solid instant-release dosage forms comprising finasteride and an anionic surfactant-methods of manufacturing thereof |
| CN1988909A (en) * | 2004-07-21 | 2007-06-27 | Gtx公司 | Compositions comprising 5-alpha reductase inhibitors and serms and methods of use thereof |
| CN101084884A (en) * | 2007-06-28 | 2007-12-12 | 托新权 | Oral film composition capable of masking pharmaceutical unpleasant flavor and preparation method thereof |
| CN103690516A (en) * | 2013-12-13 | 2014-04-02 | 重庆医药工业研究院有限责任公司 | Aripiprazole oral membrane and preparation method thereof |
-
2014
- 2014-09-24 CN CN201410489303.4A patent/CN104306354A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051344A2 (en) * | 2003-11-25 | 2005-06-09 | Pliva-Lachema A.S. | Oral solid instant-release dosage forms comprising finasteride and an anionic surfactant-methods of manufacturing thereof |
| CN1988909A (en) * | 2004-07-21 | 2007-06-27 | Gtx公司 | Compositions comprising 5-alpha reductase inhibitors and serms and methods of use thereof |
| CN101084884A (en) * | 2007-06-28 | 2007-12-12 | 托新权 | Oral film composition capable of masking pharmaceutical unpleasant flavor and preparation method thereof |
| CN103690516A (en) * | 2013-12-13 | 2014-04-02 | 重庆医药工业研究院有限责任公司 | Aripiprazole oral membrane and preparation method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104958279A (en) * | 2015-06-27 | 2015-10-07 | 万特制药(海南)有限公司 | Loratadine oral quickly-soluble film and preparation method thereof |
| CN107106512A (en) * | 2015-11-25 | 2017-08-29 | 缇碧艾姆株式会社 | Stop blooding and Wound protection film in oral cavity |
| CN105663096A (en) * | 2016-01-25 | 2016-06-15 | 南京济群医药科技有限公司 | Vonoprazan oral quick-dissolving film agent and method for preparing same |
| CN105663096B (en) * | 2016-01-25 | 2019-06-14 | 南京济群医药科技股份有限公司 | A kind of Wo Nuolazan oral quick-dissolving film preparation and preparation method thereof |
| CN118252821A (en) * | 2024-05-28 | 2024-06-28 | 山东则正医药技术有限公司 | Teriflunomide oral solution film bioequivalent to tablet and its prepn and application |
| CN118252821B (en) * | 2024-05-28 | 2024-08-13 | 山东则正医药技术有限公司 | Teriflunomide oral solution film bioequivalent to tablet and its prepn and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101159617B1 (en) | Tablet quickly disintegrating in oral cavity | |
| CN101043880B (en) | Pharmaceutical composition comprising diclofenac | |
| CN100389755C (en) | Compositions and methods for mucosal delivery | |
| CN103118662B (en) | The method preparing the heterogeneous dosage form of freeze-dried instant | |
| CN103191075B (en) | Oral medicinal preparation of tadalafil | |
| CN101632651B (en) | Oral instant membrane of risperidone and preparation method thereof | |
| JP2005139168A (en) | Composition for tablet quickly disintegrating in oral cavity | |
| CN105362240B (en) | Fast disintegrating tablet in oral cavity | |
| CN104306354A (en) | Finasteride oral instant membrane | |
| CN103974695A (en) | Bitter taste masked oral thin film formulation of sildenafil citrate | |
| CN106265580A (en) | SOMCL-9112 solid dispersion, its preparation method and comprise its SOMCL-9112 solid preparation | |
| CN107095853A (en) | A kind of oral disnitegration tablet disintegrant combination and its application method | |
| JP2017526751A (en) | Tadalafil oral disintegration film and method for producing the same | |
| CN102846581A (en) | Ambroxol hydrochloride oral fast-dissolving film and preparation method thereof | |
| CN104546807A (en) | Olanzapine oral fast dissolving film preparation | |
| CN106659751A (en) | Orodispersible film | |
| CN103263402A (en) | Water-drinking-free oral drug composition and preparation method thereof | |
| CN104644574B (en) | A kind of sildenafil citrate taste masking preparation | |
| JP5511663B2 (en) | Method for producing spherical fine particles containing tamsulosin hydrochloride | |
| JP2011026311A (en) | Method for producing tablet quickly disintegrating in oral cavity | |
| CN109010324A (en) | A kind of molten film of silaenafil mouth and preparation method thereof | |
| CN109172547A (en) | A kind of pet self-emulsifying microemulsion oral quick-dissolving film preparation and preparation method thereof | |
| TW201511781A (en) | Film formulation containing donepezil free base and manufacturing method thereof | |
| CN102784119A (en) | Roxithromycin composition freeze-dried orally disintegrating tablets and preparation method thereof | |
| CN105919982A (en) | Racecadotril oral fast dissolving film and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150128 |